Holen Sie sich die Stockscreener-App
21.26
0.38%
0.08
Schlusskurs vom Vortag:
$21.18
Offen:
$21.54
24-Stunden-Volumen:
60,915
Relative Volume:
0.82
Marktkapitalisierung:
$224.32M
Einnahmen:
$96.10M
Nettoeinkommen (Verlust:
$-31.96M
KGV:
-5.2798
EPS:
-4.0267
Netto-Cashflow:
$-25.27M
1W Leistung:
-9.15%
1M Leistung:
-26.94%
6M Leistung:
+99.81%
1J Leistung:
+215.90%
1-Tages-Spanne:
$21.02
$22.36
1-Wochen-Bereich:
$21.02
$24.99
52-Wochen-Spanne:
$5.26
$31.97
Biodesix Inc Stock (BDSX) Company Profile
Firmenname
Biodesix Inc
Sektor
Branche
Telefon
303-417-0500
Adresse
919 WEST DILLON ROAD, LOUISVILLE
Compare BDSX vs TMO, DHR, NTRA, A, IQV
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BDSX
Biodesix Inc
|
21.26 | 224.32M | 96.10M | -31.96M | -25.27M | -4.0267 |
TMO
Thermo Fisher Scientific Inc
|
684.89 | 253.24B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
232.97 | 163.77B | 24.78B | 3.68B | 5.29B | 5.1743 |
NTRA
Natera Inc
|
404.90 | 58.36B | 2.50B | -226.32M | 71.51M | -1.6412 |
A
Agilent Technologies Inc
|
175.96 | 49.61B | 7.23B | 1.41B | 1.09B | 4.979 |
IQV
Iqvia Holdings Inc
|
273.60 | 45.03B | 16.63B | 1.39B | 2.12B | 8.0674 |
Biodesix Inc Stock (BDSX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-06-25 | Eingeleitet | Roth Capital | Buy |
| 2026-06-15 | Eingeleitet | H.C. Wainwright | Buy |
| 2026-02-27 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2025-05-14 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2024-09-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-07-26 | Eingeleitet | Craig Hallum | Buy |
| 2024-05-13 | Eingeleitet | TD Cowen | Buy |
| 2024-05-03 | Eingeleitet | Lake Street | Buy |
| 2021-11-17 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-11-23 | Eingeleitet | BTIG Research | Buy |
| 2020-11-23 | Eingeleitet | Canaccord Genuity | Buy |
| 2020-11-23 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-11-23 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Biodesix Inc Aktie (BDSX) Neueste Nachrichten
Biodesix Adds Digital Diagnostics to Lung Pipeline, Creating New Growth Platform Combining Blood and Imaging Biomarkers - GlobeNewswire Inc.
A test in development will pair blood results with lung scans to assess lung cancer risk - Stock Titan
Form 4 Biodesix Inc: John Patience (Director, Chairman) For: 30 September By Investing.com - Investing.com South Africa
Form 4 Biodesix Inc: John Patience (Director, Chairman) For: 30 September - Investing.com UK
Biodesix to Present New Real-World Evidence Supporting Integration of Nodify Lung® Testing into Routine Lung Nodule Care at CHEST 2026 - GlobeNewswire Inc.
Beat the Market Like Zacks: Thermo Fisher, Cricut, Shopify in Focus - Zacks Investment Research
Converting 1,360 stock units leaves Biodesix (BDSX) chairman with 26,743 shares held directly. - Stock Titan
Biodesix Inc (NASDAQ: BDSX) Stock Price, News & Analysis - kalkine.ca
A Look at Biodesix Inc (BDSX) After 3.5% Gain -- GF Value $21.14 vs Price $26.96 - GuruFocus
Opaleye Management Inc. Cuts Position in Biodesix, Inc. $BDSX - marketbeat.com
Biodesix: Growing Fast While Trading Below Many Diagnostics Peers (NASDAQ:BDSX) - Seeking Alpha
Biodesix, Inc. (NASDAQ:BDSX) Given Consensus Recommendation of "Moderate Buy" by Analysts - marketbeat.com
BlackRock Inc. Invests $970,000 in Biodesix, Inc. $BDSX - marketbeat.com
Biodesix to Participate in Upcoming Investor Conferences - The Manila Times
Biodesix to Participate in Upcoming Investor Conferences - Moomoo
BioDesix (NASDAQ:BDSX) Passes Minervini Trend Template but Setup Quality Remains Weak - ChartMill
What Makes Biodesix, Inc. (BDSX) a Strong Momentum Stock: Buy Now? - Yahoo Finance
Biodesix Inc (BDSX) Stock Up 9.0% but GF Value Says Overvalued -- GF Score: 51/100 - GuruFocus
Does Biodesix (BDSX) Have the Potential to Rally 103.33% as Wall Street Analysts Expect? - qz.com
PRPO vs. BDSX: Which Cancer Diagnostics Stock Is the Better Buy Now? - The Globe and Mail
Biodesix (BDSX) Q2 2026 Results: The Bottom-Line Figure Outpaces Its Comparison on the Day; After Earnings: The Stock Loses 5.91% in the Latest SessionCEO Earnings Statement - vinanet.vn
Biodesix (BDSX) Q2 2026 Results: The Bottom-Line Figure Outpaces Its Comparison on the Day; After Earnings: The Stock Loses 5.91% in the Latest SessionEarnings Revision Report - dars.gov.et
Biodesix (BDSX) Q2 2026 Results: The Bottom-Line Figure Outpaces Its Comparison on the Day; After Earnings: The Stock Loses 5.91% in the Latest SessionFinancial Health Score - dars.gov.et
Biodesix (BDSX) Results Check: The Bottom-Line Figure Beats Its Comparison; After Earnings: The Market Price Declines 3.91% in Latest TradingGuidance Accuracy Score - vinanet.vn
Biodesix (BDSX) Results Check: The Bottom-Line Figure Beats Its Comparison; After Earnings: The Market Price Declines 3.91% in Latest TradingMargin Expansion Trends - dars.gov.et
46,989 Shares in Biodesix, Inc. $BDSX Purchased by GSA Capital Partners LLP - MarketBeat
AIGH Capital Management LLC Acquires New Stake in Biodesix, Inc. $BDSX - MarketBeat
Biodesix (BDSX) Edges Higher at $24.0 as Bulls Defend Key SupportVol Target Rebalance - vinanet.vn
Walleye Capital LLC Makes New $1.68 Million Investment in Biodesix, Inc. $BDSX - MarketBeat
Sei Investments Co. Makes New Investment in Biodesix, Inc. $BDSX - MarketBeat
Biodesix (BDSX) Edges Higher at $24.0 as Bulls Defend Key SupportTRIN Signal - dars.gov.et
Biodesix Stock Price Forecast. Should You Buy BDSX? - StockInvest.us
BDSX Q2 2026 Earnings: EPS Beats Estimates by 22.85% as Loss NarrowsEarnings Preview - vinanet.vn
BDSX | Biodesix, Inc. Common Stock FinancialsRevenue Breakdown - Quiver Quantitative
Biodesix director Jack Schuler buys company stock, valued at $366,991 By Investing.com - Investing.com India
Biodesix director Jack Schuler buys company stock, valued at $366,991 By Investing.com - Investing.com Australia
Biodesix director Jack Schuler buys company stock, valued at $366,991 By Investing.com - Investing.com Nigeria
Biodesix director Jack Schuler buys company stock, valued at $366,991 - Investing.com
Biodesix director Jack Schuler buys company stock, valued at $366,991 - Investing.com
BDSX Q2 2026 Earnings: Narrower Loss Beats Estimates as Shares Dip 1.78Earnings Yield Spread - Vinanet
Biodesix (NASDAQ:BDSX) Director Jack Schuler Buys 15,000 Shares of Stock - MarketBeat
Biodesix Insider Bought Shares Worth $366,992, According to a Recent SEC Filing - marketscreener.com
Biodesix Inc (BDSX) major holder Jack W. Schuler buys 15,000 shares - Stock Titan
Biodesix, Inc. (NASDAQ:BDSX) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Biodesix Insider Bought Shares Worth $366,992, According to a Recent SEC Filing - Yahoo Finance
Biodesix director Jack Schuler buys $665,940 in company stock By Investing.com - Investing.com Australia
Biodesix (NASDAQ:BDSX) Director Jack Schuler Purchases 13,700 Shares of Stock - MarketBeat
Insider Buying: Biodesix (NASDAQ:BDSX) Director Purchases 13,900 Shares - MarketBeat
Biodesix director Jack Schuler buys $665,940 in company stock By Investing.com - Investing.com Canada
Biodesix director Jack Schuler buys $665,940 in company stock - Investing.com India
Finanzdaten der Biodesix Inc-Aktie (BDSX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Biodesix Inc-Aktie (BDSX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| SCHULER JACK W | Emeritus Director |
Aug 11 '26 |
Buy |
24.01 |
13,700 |
328,911 |
540,810 |
| SCHULER JACK W | Emeritus Director |
Aug 10 '26 |
Buy |
24.25 |
13,900 |
337,029 |
527,110 |
| O'Kane Kieran | Chief Commercial Officer |
Feb 23 '26 |
Sale |
12.78 |
535 |
6,835 |
9,819 |
| Cowie Robin Harper | CFO, Sec'y & Treasurer |
Feb 23 '26 |
Sale |
12.78 |
535 |
6,835 |
16,231 |
| Vazquez Chris | Chief Accounting Officer |
Feb 23 '26 |
Sale |
12.78 |
211 |
2,696 |
1,586 |
| Hutton Scott | President & CEO |
Feb 23 '26 |
Sale |
12.78 |
1,490 |
19,036 |
48,767 |
| Hutton Scott | Officer |
Feb 23 '26 |
Proposed Sale |
12.77 |
1,490 |
19,027 |
0 |
| Pestano Gary Anthony | Chief Development Officer |
Feb 23 '26 |
Sale |
12.78 |
556 |
7,103 |
10,359 |
| O'Kane Kieran | Chief Commercial Officer |
Feb 10 '26 |
Sale |
10.08 |
584 |
5,889 |
8,885 |
| Vazquez Chris | Chief Accounting Officer |
Feb 10 '26 |
Sale |
10.08 |
101 |
1,018 |
1,234 |
2.75%
5.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):